Video

Zanubrutinib plus Obinutuzumab versus Obinutuzumab in Patients with Relapsed/Refractory Follicular Lymphoma: Updated Analysis of the ROSEWOOD Study

Author(s):

Christopher Flowers, MD

Dr. Christopher Flowers showcases a comprehensive and updated analysis of the ROSEWOOD study, evaluating the efficacy and safety of combining zanubrutinib with obinutuzumab versus obinutuzumab monotherapy.

Related Videos
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, highlight key data in CML and ALL presented at the 2024 ASH Annual Meeting.
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, detail factors for selecting a TKI in later lines of therapy in chronic myeloid leukemia.
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss data for ponatinib plus chemotherapy in Ph-positive ALL.
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss dosing strategies for ponatinib in CML and ALL.
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, on the implications of the mutational analysis for ponatinib in the OPTIC trial in CP-CML.
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss 5-year data for ponatinib in pretreated CP-CML.
RLY-2608
BOVen
Naval G. Daver, MD,
RMC-6236
Related Content
Acute Myeloid Leukemia | stock.adobe.com
January 23rd 2025

Maintenance Galinpepimut-S Appears Effective and Safe in AML in Second CR

Paul J. Shaughnessy, MD, medical director, Adult Blood and Marrow Stem Cell Transplant Program, Methodist Hospital
November 28th 2024

FDA Approval Insights: Obe-Cel in B-Cell Precursor ALL

US FDA
January 16th 2025

Tabelecleucel BLA Receives FDA CRL in Pretreated EBV+ Post-Transplant Lymphoproliferative Disease

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Michael T. Tees, MD, MPH, of Colorado Blood Cancer Institute
January 12th 2025

BTK Degraders Look to Fill Unmet Need for Patients With Pretreated B-Cell Malignancies

Christopher Graham, MD, of University of Minnesota Medical School
January 10th 2025

Axatilimab Shakes Up cGVHD Treatment and Looks to Move to Earlier Line in Paradigm